Market Report Source

Overview

Introduction
Urge urinary incontinence (UUI) is a relatively common disorder which can affect all age groups but becomes increasingly prevalent with old age. Although several pharmacological therapies are available for treating this distressing condition, patients’ reluctance to present to a physician and incorrect diagnosis of the different overactive bladder subtypes limit the potential of this market.

Scope
Quantitative treatment data from 418 physicians based in US, Japan, France, Germany, Italy, Spain and UK; supported by key opinion leader comments
Analysis of epidemiology, presentation and referral patterns, diagnostic assessment, and first- to third-line treatments for UUI
Influences on treatment choice and perception of current drug therapies including tolterodine, oxybutynin, darifenacin and solifenacin
Evaluation of unmet needs and future outlook including awareness of R&D drug pipeline

Highlights
Although the prevalence of UUI in women is high, the potential of this market is limited by the reluctance of patients to present to a physician for treatment. Direct to consumer advertising, where available, has already increased awareness and presentation of this condition but other strategies are also required to assist in enlarging the market.

In theory, UUI could be managed successfully by PCPs. However, there is little belief in their ability to correctly diagnose the subtypes of OAB and this lack of confidence is supported by inappropriate prescribing trends by PCPs. Methods to address diagnosis and treatment of UUI in the primary care setting should reflect the priorities of PCPs.

Older treatments for UUI are associated with a number of unpleasant side effects, leaving significant unmet need in this market. Several new products have recently entered the market yet there is little perceived differentiation from existing treatments. Emphasizing the improved efficacy and side effect profiles is key to improving uptake.

Reasons to Purchase
Forecast product sales by understanding key aspects of UUI epidemiology, diagnosis and treatment
Gain a better understanding of the challenges facing current and future players in the UUI market
Identify physicians key concerns in UUI including unmet needs and the attributes that physicians believe are desirable for future treatments

Table of Contents

TABLE OF CONTENTS

OVERVIEW

This product has been designed for delivery in a slide pack format (PowerPoint).

Please select the slide pack option from the download menu at the side of the page

Introduction

Scope of this report

Research and analysis highlights

Key reasons to read this report

APPENDIX A

Research methodology

Physician Sample breakdown

Urinary Incontinence and Overactive Bladder Insight Study – Physician Questionnaire

Section One Overview of Urinary Incontinence and overactive Bladder

Epidemiology

Presentation

Diagnosis

Referral pattern

Section Two Stress Urinary Incontinence

Diagnosis and treatment of SUI

Non-pharmacological treatment

Pharmacological treatment for SUI

Section Three Overactive Bladder With Urge Symptoms and/or Incontinence

Diagnosis and treatment of UUI

Pharmacological treatment for UUI

Diagnosis and treatment of ‘dry OAB’

Pharmacological treatment for dry OAB

Section Four Mixed Stress/Urge Urinary Incontinence

Diagnosis and treatment of mixed SUI/UUI

Non-pharmacological treatment

Pharmacological treatment for mixed SUI/UUI

Section Five Interstitial Cystitis

Diagnosis and treatment of IC

Pharmacological treatment for IC

Section Six Drug Profiles

Section A: Drug influences on physicians’ choice

Section B: The general treatment of urinary incontinence and overactive bladder

Contributing experts

US

Japan

Europe

APPENDIX B

About Datamonitor

About Datamonitor Healthcare

About the CNS analysis team

Disclaimer